A report on the impact of biosimilar competition in Europe

A white paper published by IQVIA discusses the many factors affecting the impact of biosimilars, from price policies to IP protection strategies. The document also proposes a set of KPIs useful to better asses this relevant sector, and offers a detailed analysis of many biosimilars already present in the European market and medicines close to reach patent expiry